AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34612583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 54
Study 35213345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-Plus Stabilization Exercise (VSE)
Number of subjects: 62
Study 35213345 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stabilization Exercise (CSE)
Number of subjects: 62
Study 35415837 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating exoscope
Number of subjects: 28
Study 35415837 — intervention group
Group type: COMPARATOR
Intervention: Operating microscope
Number of subjects: 28
Study 35415837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation experience
Number of subjects: 28
Study 33658358 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 0
Study 33658358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36307314 — intervention group
Group type: EXPERIMENTAL
Intervention: Qili Qiangxin Capsule combined with cardiac exercise rehabilitation
Number of subjects: 93
Study 36307314 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 93
Study 34443468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with hydrolyzed fish cartilage for 90 days
Number of subjects: 46
Study 34443468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34758186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative application of ciprofloxacin drops
Number of subjects: 256
Study 34758186 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 5 day postoperative application of ciprofloxacin drops
Number of subjects: 256
Study 34758186 — intervention group
Group type: COMPARATOR
Intervention: No drops (control)
Number of subjects: 256
Study 33893355 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric high-protein diets
Number of subjects: 31
Study 33893355 — intervention group
Group type: COMPARATOR
Intervention: Liver fat indices
Number of subjects: 31
Study 33893355 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-independent diets
Number of subjects: 31
Study 35427193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track Friendship Group program (n = 110)
Number of subjects: 224
Study 35427193 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group (n = 114)
Number of subjects: 224
Study 34304292 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength exercise (twice weekly for 10 weeks)
Number of subjects: 40
Study 34304292 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 40
Study 33168045 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated GTV-TNM stratification system
Number of subjects: 340
Study 36231353 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation combined with Motor Imagery (AO + MI)
Number of subjects: 45
Study 36231353 — intervention group
Group type: COMPARATOR
Intervention: Action Observation (AO)
Number of subjects: 45
Study 33951895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Vision Quality of Life Questionnaire (LVQOL)
Number of subjects: 64
Study 33951895 — intervention group
Group type: EXPERIMENTAL
Intervention: National Eye Institute Visual Function Questionnaire (NEI VFQ‐25)
Number of subjects: 64
Study 32770612 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus gabapentin titrated to drug tolerance during radiation
Number of subjects: 79
Study 32770612 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 36214928 — intervention group
Group type: EXPERIMENTAL
Intervention: CHPE150
Number of subjects: 30
Study 36214928 — intervention group
Group type: EXPERIMENTAL
Intervention: CHPE300
Number of subjects: 30
Study 36214928 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 30
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination strategy (including at least two blood pressure lowering agents plus a statin, with or without aspirin)
Number of subjects: 18162
Study 34469765 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or usual care)
Number of subjects: 18162
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination strategy (with aspirin)
Number of subjects: 18162
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination strategy (without aspirin)
Number of subjects: 18162
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination strategy
Number of subjects: 18162
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination strategy with aspirin
Number of subjects: 18162
Study 34469765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18162
Study 34469765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination treatment
Number of subjects: 18162
Study 32142113 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation on continuous anticoagulation
Number of subjects: 633
Study 36071463 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychosocial intervention (Viva Vida) delivered via WhatsApp, sending psychoeducational and behavioural activation audio and visual messages 4 days a week for 6 weeks.
Number of subjects: 500
Study 36071463 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a single message with general information about depression.
Number of subjects: 500
Study 36071463 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychosocial intervention (Viva Vida)
Number of subjects: 500
Study 33865218 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic balance training (SG)
Number of subjects: 39
Study 35227311 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic mammoplasty
Number of subjects: 20
Study 35227311 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 20
Study 34521398 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin nanomicelle capsules 80 mg twice a day for 7 weeks
Number of subjects: 50
Study 34521398 — intervention group
Group type: COMPARATOR
Intervention: Placebo two times a day for 7 weeks
Number of subjects: 50
Study 35606094 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour nap opportunity (8 + 1)
Number of subjects: 12
Study 35606094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour nap opportunity (7 + 2)
Number of subjects: 12
Study 35606094 — intervention group
Group type: COMPARATOR
Intervention: 9 hours in bed overnight without a nap opportunity (9 + 0)
Number of subjects: 12
Study 33607625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR, n = 6)
Number of subjects: 12
Study 33607625 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n = 6)
Number of subjects: 12
Study 32701820 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific risk scores for women aged 18-24
Number of subjects: 0
Study 32701820 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific risk scores for women aged 25-35
Number of subjects: 0
Study 32701820 — intervention group
Group type: COMPARATOR
Intervention: VOICE risk score applied to women aged 18-35
Number of subjects: 0
Study 32701820 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 incidence among women aged 18-24
Number of subjects: 0
Study 35840303 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention 1
Number of subjects: 3
Study 35840303 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention 2
Number of subjects: 3
Study 35840303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 3
Study 33608413 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Beginnings (SB) intervention including Video Interaction Project (VIP) and Family Check-Up
Number of subjects: 403
Study 35738297 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based training (self-learning using digital instructional materials)
Number of subjects: 80
Study 35738297 — intervention group
Group type: COMPARATOR
Intervention: Stationary microsurgical course with tutor supervision
Number of subjects: 80
Study 32101271 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine and sertraline
Number of subjects: 88
Study 32101271 — intervention group
Group type: COMPARATOR
Intervention: Placebo and sertraline
Number of subjects: 88
Study 34996948 — intervention group
Group type: EXPERIMENTAL
Intervention: MCALP group: 0.5 g of methylprednisolone intravenously for three consecutive days at the beginning of the course and 3rd month, oral prednisone at a dose of 15 mg every other day for 6 months
Number of subjects: 87
Study 34996948 — intervention group
Group type: COMPARATOR
Intervention: FP group: 0.8-1.0 mg/kg/days of prednisone (maximum 70 mg/day) for 2 months, then tapered by 5 mg every 10 days for the next 4 months
Number of subjects: 87
Study 34776174 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 2 weeks, 40 min/session, 3 sessions/week
Number of subjects: 30
Study 34776174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 32819927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1 mg/day in weeks 1-8, 1 mg/week in weeks 9-52)
Number of subjects: 283
Study 32819927 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vitamin B12 (1 mg on alternate days in weeks 1-2, 1 mg/week in weeks 3-8, 1 mg/month in weeks 9-52)
Number of subjects: 283
Study 32819927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12
Number of subjects: 283
Study 32819927 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vitamin B12
Number of subjects: 283
Study 32819927 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and adverse effects
Number of subjects: 283
Study 32819927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 283
Study 35993635 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine
Number of subjects: 60
Study 35993635 — intervention group
Group type: COMPARATOR
Intervention: Non-TAP block
Number of subjects: 60
Study 34626927 — intervention group
Group type: EXPERIMENTAL
Intervention: LB 266 mg TAP block alone
Number of subjects: 153
Study 34626927 — intervention group
Group type: EXPERIMENTAL
Intervention: ITM 50 μg followed by LB 266 mg TAP block
Number of subjects: 153
Study 34626927 — intervention group
Group type: COMPARATOR
Intervention: ITM 150 μg alone
Number of subjects: 153
Study 34626927 — intervention group
Group type: EXPERIMENTAL
Intervention: LB 266 mg TAP block alone and LB + ITM group
Number of subjects: 153
Study 34626927 — intervention group
Group type: EXPERIMENTAL
Intervention: LB + ITM group
Number of subjects: 153
Study 34626927 — intervention group
Group type: COMPARATOR
Intervention: ITM group
Number of subjects: 153
Study 36753778 — intervention group
Group type: EXPERIMENTAL
Intervention: MLM-CBRN Preparedness Program
Number of subjects: 104
Study 36753778 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 33629258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor antagonist)
Number of subjects: 120
Study 33629258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32474473 — intervention group
Group type: EXPERIMENTAL
Intervention: Matured Hop Bitter Acids (MHBA)
Number of subjects: 100
Study 32474473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34063799 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational plus family weight loss (M + FWL) intervention
Number of subjects: 241
Study 34063799 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 241
Study 33248594 — intervention group
Group type: EXPERIMENTAL
Intervention: HL group (high-low Zn, basal diets supplemented 120 mg/kg Zn)
Number of subjects: 162
Study 33248594 — intervention group
Group type: EXPERIMENTAL
Intervention: LH group (low-high Zn, basal diets supplemented 120 mg/kg Zn)
Number of subjects: 162
Study 35714722 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 30
Study 35714722 — intervention group
Group type: COMPARATOR
Intervention: Existing institutional patient educational material (PEM)
Number of subjects: 30
Study 32919915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 881
Study 32919915 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study 35653412 — intervention group
Group type: EXPERIMENTAL
Intervention: TFTD→Rego group
Number of subjects: 69
Study 35653412 — intervention group
Group type: EXPERIMENTAL
Intervention: TFTD+Bev→Rego group
Number of subjects: 69
Study 35653412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rego→TFTD group
Number of subjects: 69
Study 32476445 — intervention group
Group type: EXPERIMENTAL
Intervention: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI)
Number of subjects: 30
Study 32476445 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MFx)
Number of subjects: 30
Study 35617520 — intervention group
Group type: EXPERIMENTAL
Intervention: napabucasin plus paclitaxel
Number of subjects: 714
Study 35617520 — intervention group
Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 714
Study 33824441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care intervention during HCT
Number of subjects: 160
Study 32925145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention in female breast and gynaecological cancer survivors
Number of subjects: 65
Study 32925145 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 65
Study 35656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide with ADT and docetaxel
Number of subjects: 1306
Study 35656777 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ADT and docetaxel
Number of subjects: 1306
Study 34282267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin intramuscular injections (0.5 mg/day, 3 times/week)
Number of subjects: 32
Study 34282267 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamin oral tablets (1.5 mg/day)
Number of subjects: 32
Study 33130252 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 15 min) to the prefrontal cortex
Number of subjects: 40
Study 33130252 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 36432469 — intervention group
Group type: EXPERIMENTAL
Intervention: P-CHO (20 g of Pronativ®, native whey protein and 60 g of carbohydrate)
Number of subjects: 12
Study 36432469 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (80 g of carbohydrate)
Number of subjects: 12
Study 36432469 — intervention group
Group type: EXPERIMENTAL
Intervention: P-CHO
Number of subjects: 12
Study 36432469 — intervention group
Group type: EXPERIMENTAL
Intervention: P-CHO and CHO
Number of subjects: 12
Study 36432469 — intervention group
Group type: COMPARATOR
Intervention: PLA (nonenergetic chocolate‐flavored drink)
Number of subjects: 12
Study 32339048 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 60
Study 32339048 — intervention group
Group type: COMPARATOR
Intervention: Traditional trans‐nasal trans‐speculum (TNTS) septoplasty
Number of subjects: 60
Study 35396528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic condition (4.5 min ischemia + 0.5 min reperfusion)
Number of subjects: 10
Study 35396528 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no ischemia)
Number of subjects: 10
Study 35623611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) for 4 hours per day for 60 days
Number of subjects: 72
Study 35623611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 72
Study 33341644 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 244
Study 33341644 — intervention group
Group type: COMPARATOR
Intervention: no‐CPAP
Number of subjects: 244
Study 32469384 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib (600 mg orally once daily)
Number of subjects: 60
Study 32469384 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Number of subjects: 60
Study 33251910 — intervention group
Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 150
Study 32243609 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg daily oral iron
Number of subjects: 193
Study 32243609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 193
Study 34033125 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 82
Study 34033125 — intervention group
Group type: COMPARATOR
Intervention: GIC along with fluoride varnish (FV)
Number of subjects: 82
Study 32718800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Antenatal Care (EAC)
Number of subjects: 32
Study 32718800 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 32
Study 32375553 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 11222
Study 35811090 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) (test; n=20)
Number of subjects: 40
Study 35811090 — intervention group
Group type: COMPARATOR
Intervention: Contour augmentation (control; n=20)
Number of subjects: 40
Study 33938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0
Study 33938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0
Study 33938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting enteral feeds during packed red blood cell (PRBC) transfusions
Number of subjects: 0
Study 33938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding feeds during PRBC transfusions
Number of subjects: 0
Study 32476816 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tears and 0.1% fluorometholone eye drops three times a day (G-DESOS group)
Number of subjects: 39
Study 32476816 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears only (C-DESOS group)
Number of subjects: 39
Study 32476816 — intervention group
Group type: COMPARATOR
Intervention: N/A (CMDE and control groups)
Number of subjects: 39
Study 616270988 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A + intensive physiotherapy (iPT)
Number of subjects: 65
Study 616270988 — intervention group
Group type: COMPARATOR
Intervention: Only intensive physiotherapy (iPT)
Number of subjects: 65
Study 34075784 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukon Choice PC (biodegradable polymer-based sirolimus-eluting stents)
Number of subjects: 1951
Study 34075784 — intervention group
Group type: COMPARATOR
Intervention: Xience (permanent polymer-based everolimus-eluting stents)
Number of subjects: 1951
Study 34075784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus
Number of subjects: 1951
Study 34075784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without diabetes mellitus
Number of subjects: 1951
Study 34075784 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite/probable stent thrombosis
Number of subjects: 1951
Study 33273644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanyl target infusion based on the pupillary pain index
Number of subjects: 50
Study 33273644 — intervention group
Group type: COMPARATOR
Intervention: Standard sufentanyl target infusion left to the discretion of the anesthesiologist (Control)
Number of subjects: 50
Study 35477731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose (IV iron)
Number of subjects: 54
Study 35477731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 32871095 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypocaloric Mediterranean diet
Number of subjects: 121
Study 32871095 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (standard pediatric recommendations)
Number of subjects: 121
Study 32871095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 121
Study 34083348 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NMES
Number of subjects: 22
Study 34083348 — intervention group
Group type: COMPARATOR
Intervention: Placebo NMES
Number of subjects: 22
Study 34083348 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care (home-based exercise, weekly telephone support, breathlessness management leaflet) with either placebo or active NMES for 6 weeks
Number of subjects: 22
Study 34083348 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative findings from purposively sampled participants
Number of subjects: 22
Study 35985109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection using Neoteryx Mitra Clamshell, n = 136
Number of subjects: 312
Study 35985109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection using Tasso-SST, n = 176
Number of subjects: 312
Study 35985109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection using Neoteryx Mitra Clamshell and Tasso-SST
Number of subjects: 312
Study 34138615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (verbalize vaccination reasons)
Number of subjects: 161
Study 34138615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (choose HPV topics)
Number of subjects: 161
Study 34138615 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation scores
Number of subjects: 161
Study 32588429 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PBC)
Number of subjects: 495
Study 32588429 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PBC)
Number of subjects: 495
Study 32588429 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC doublets
Number of subjects: 495
Study 32588429 — intervention group
Group type: COMPARATOR
Intervention: Non-PBC doublets
Number of subjects: 495
Study 32588429 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC in first-line therapy
Number of subjects: 495